Skip to main content

Table 1 Active drug score (ADS) for the follow-up therapy

From: The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

  GROUP A GROUP B
Pat-ID #1 #2 #4 #12 #14 #17 #18 #21 #22 #46 #3 #5 #8 #9 #10 #11 #16 #19 #24 #25 #26 #27 #31 #33 #37 #39 #40 #41
Therapy ATV SQV RTV FTC ATV SQV
RTV 3TC
ATV SQV RTV ATV/r SQV
3TC
T20
SQV
TPV/r
3TC
ddI
ddI
d4T
SQV
ATV
SQV
3TC
T20
ATV
EFV
TDF
AZT
3TC
MVC
ATV/r
SQV
AZT
3TC
TDF
SQV/r
TDF
FTC
LPV/r
SQV
3TC
d4T
TDF
LPV/r
ATV
AZT
3TC
LPV/r
SQV
d4T
LPV/r
SQV
ENF
LPV
ATV
FTC
TDF
LPV/r
ATV
EFV
LPV/r
SQV
LPV/r
SQV
APV
SQV
TDF
APV
SQV
ddC
d4T
APV/r
SQV
LPV/r
SQV
FTC
TDF
LPV/r
SQV
3TC
ETR
LPV/r
SQV
AZT
3TC
TDF
LPV/r
SQV
ddI
3TC
LPV/r
SQV
TDF
LPV/r
SQV
TDF
MVC
LPV/r
ATV
TDF
AZT
ABC
3TC
Rev.-Transcriptase mutations 41L
44D
67N
98G
103N
118I
210F
215Y
219R
41L
67ss
69S
188L
215Y
41L
118I
184V
215Y
41L
44A
67N
75I
103N
108I
118I
210W
215Y
41L
67N
69D
70R
74V
103N
181C
210W
215F
219Q
67N
70R
103NS
190A
184V
219Q
41L
67N
69E
75I
103N
108I
118I
178M
210W
215Y
41L
67N
74V
101Q
184V
215Y
41L
44D
67N
101E
103N
118I
184V
210W
215Y
219E
n.d. 41L
67ss
69S
101Q
181C
190S
215Y
65R
70R
103N
108I
115F
151M
179E
184V
219E
67N
184V
210W
215Y
219Q
41L
44D
67N
75L
118I
181C
184V
190A
210S
215Y
41L
44D
67N
70R
190A
227L
184V
210W
215F
219R
41L
67N
74V
98G
118I
184V
210W
215Y
227L
41L
44D
103N
118I
184V
210W
215Y
no
data
no
data
no
data
67N
70R
103S
184V
190A
215F
219Q
41L
67N
75I
118I
210W
215F
41L
44A
67N
75M
101Q
118I
184V
210W
215F
41L
74V
101Q
103N
108I
181C
190A
210W
215Y
41L
44D
67G
103N
118I
184V
210W
215F
67N
70R
215I
219Q
67N
70R
215I
219Q
41L
67N
70R
184V
Protease mutations 10F
20I
36I
46I
50V
54I/V
76V
10V
46I
47V
71V
76V
77I
10V
20R
36I
46I
76V
90M
10I
33F
46L
76V
82F
90M
10V
20R
33F
36I
54V
73S
76V
90M
10F
20R
46I
54V
63P
76V
82F
10I
33F
36L
46L
76V
82F
84V
90M
10I
53L
54V
71V
76V
77I
82A
84V
90M
10I
33F
46L
54V
71I
76V
77L
82A
90M
10I
33V
60E
76V
10V
46L
54V
63P
71V
82A
93L
10I
20I
36I
46I
54L
76V
84V
20R
32I
46I
76V
82A
10I
24I
33F
46I
54V
63P
71V
76V
82A
10V
20I
36I
46I
47V
53L
76V
84V
90M
10F
33F
46L
54L
71V
76V
77I
84V
90M
10F
46I
54M
71V
76V
82A
10I
20R
24I
36I
46I
54V
76V
82C
10F
33F
54V
71V
76V
77I
82A
10I
20R
35D
46I
54V
76V
10I
20R
36I
46I
54V
71V
76V
82F
90M
10I
46I
47V
71V
76V
90M
10I
13V
32I
33F
36I
46I
76V
84V
90M
10F
46I
47V
76V
84V
10R
32I
33F
46I
47V
76V
84V
88S
90M
10F
20I
36I
46I
76V
84V
10V
13V
24I
33F
46I
54V
76V
82A
20I
36I
54V
76V
82A
Active Drug Scores                             
   HIVdb 4.3.6 [1.5] (2.25) 0.5 [1.75] 0.75 1,25 [1.5] [1.75] 0.25 3.0 1,5 [0.5] [0.75] 1.25 0.25 [0.75] [0.5] [0.5] 1.5 n.d. 0.5 [1.25] [0.25] [1.5] 0.0 [1.0] [1.75] [1.75]
   Rega V7.1.1 2.0 (2.75) 1.5 2.0 1.0 1.0 2.0 3.5 0.0 3.0 1.75 [1.0] [1.5] 1.0 0.0 [0.25] [0.75] [0.75] 1.75 n.d. 0.75 [1.0] [0.5] 2.75 0.5 2.0 2.25 4.25
   HIVGrade04/08 2.5 (3.0) 1.5 2.25 1.0 0.5 2.75 2.75 0.0 3.0 (2.0) [1.0] [1.0] (2.0) 0.0 [1.0] [1.0] [1.0] (2.0) n.d. 1.0 [1.75] [0.0] [1.75] 0.0 [0.75] 2.0 2.0
   ANRS 10/2007 3.0 (2.0) 0.5 [1.0] 1.0 1.0 2.0 2.5 0.5 3.0 1.5 [0.0] 2.0 1.0 0.5 [1.0] [1.0] [0.5] (2.0) n.d. 0.5 2.0 [0.5] 2.5 1.5 [1.5] 2.5 3.0
   geno2pheno 2.0 (3.0) 1.0 2.5 (2.0) n.d. n.d. 2.0 n.d. 3.0 (2.0) [0.5] [0.5] 1.5 0.0 [1.0] n.d. n.d. n.d. n.d. 0.0 2.5 n.d. 2.0 0.0 1.0 2.0 4.0
   VircoType 2.25 (2.0) (2.0) 2.5 1.5 n.d. n.d. 3.5 n.d. 3.0 2.5 2.0 2.0 1.0 0.5 [0.5] [1.0] [1.0] n.d. n.d. 0.5 [1.0] [1.0] 3.0 1.5 2.0 3.0 3.5
   Phenotype 2.5 n.d. 0.0 n.d. n.d. (3.0) 3.0 3.0* n.d. n.d. n.d. 2.5 2.5 (2.0) n.d. n.d. n.d. [0.5] n.d. n.d. 0.0 n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Follow-up                             
   Baseline VL 1070 160000 26900 3231 47653 859000 7700 27000 35400 4248 6680 25900 4840 31400 39000 20163 8751 8800 88100 16100 310510 < 50 72100 14900 1300 744 2078 443
   Lowest VL (12-96 weeks) < 50 3410 38700 < 50 4943 190 < 50 < 50 1020 < 50 1320 < 50 < 50 116 24000 < 50 < 50 < 50 559 < 50 18270 < 50 < 50 < 50 1300 < 50 < 50 < 50
   VL at week 96 13589 46570 152000 < 50 20626 LFU LFU LFU 16500 LFU LFU < 50 < 50 116 LFU < 50 < 50 LFU LFU 1777 LFU 391 60 < 50 LFU < 50 < 50 < 50
  1. Based on five genotypic resistance interpretation tools as well as two phenotypic resistance tests, an active drug score (ADS) for the follow-up therapy was calculated by adding the activity score for every active drug ranging from AS = 1.0 for complete sensitivity, AS = 0.75 for potential low-level resistance, AS = 0.5 for intermediate resistance, AS = 0.25 for possible resistance and AS = 0.0 for complete resistance. Their prediction on follow-up therapy was then compared with the virological response in a time frame of 96 weeks. Sucessfull therapies despite an active drug score prediction of <2 are displayed in bold and square brackets. Unsucessfull therapies despite an active drug score prediction of ≥2 are displayed in round brackets. LFU=loss of follow-up.